Analysts See $0.90 EPS for Valeant Pharmaceuticals International, Inc. (VRX) on May, 8

April 17, 2018 - By Anthony Romero

Valeant Pharmaceuticals International, Inc. (TSE:VRX) Corporate Logo

Valeant Pharmaceuticals International, Inc. (TSE:VRX)’s earnings report is anticipated On May, 8., according to Faxor. The earnings per share diference is $2.81 or 75.74 % down from last years number. Previous year: $3.71; Analysts forcast: $0.90. T_VRX’s profit could be $326.05 million with 6.01 P/E in case $0.90 earnings per share is reported. Last quarter $1.24 earnings per share was reported. Analysts predicts -27.42 % negative EPS growth this quarter. Its shares touched $21.63 on during the last trading session after 0.05% change.Currently Valeant Pharmaceuticals International, Inc. is after 0.00% change in last April 17, 2017. VRX has 1.06M shares volume. VRX underperformed by 11.55% the S&P 500.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide.The firm is worth $7.84 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S.3.17 is the P/E ratio. Diversified Products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: